SCHEMBL8248377

SCHEMBL8248377

CC1(C)[C@@H]2[C@H]3C(=O)N[C@H](C(=O)C(N)=O)CCCCCCCCC[C@H](NC(=O)N[C@H](C(=O)C4CC4)C4CCCCC4)C(=O)N3C[C@@H]21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8291298 1.00 — —
SCHEMBL16349664 0.94 — —
SCHEMBL8255465 0.89 — —
SCHEMBL8290586 0.89 — —
SCHEMBL13685690 0.88 CTSV (0.35) —
SCHEMBL16297979 0.87 — —
SCHEMBL8257386 0.87 — —
SCHEMBL16349662 0.83 — —
SCHEMBL7857551 0.83 CTSV (0.33) —
SCHEMBL12607828 0.82 CCR2 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 — — US disclosed
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 — — US disclosed
WO-2006113942-A2 METHOD OF INHIBITING CATHEPSIN ACTIVITY SCHERING CORPORATION (US) 2006-10-26 — — WO disclosed
Send feedback